References

  1. CAPLYTA full prescribing information, 2019.
  2. Lieberman JA, Davis RE, Correll CU, et al. CAPLYTA for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry. 2016;79(12):952-961.
  3. Data on File. 2019.
  4. Correll CU, Davis RE, Weingart M, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(4):349-358.
  5. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28-37.
  6. Shankar G, Nate C. Positive and Negative Syndrome Scale as a long-term outcome measurement tool in patients receiving clozapine ODT- A Pilot Study. Pharm Pract (Granada). 2007;5(1):42-45.
  7. Davis RE, Correll CU. CAPLYTA in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Rev Neurother. 2016;6(16):601-614.
  8. Kumar B, Kuhad A, Kuhad A. Lumateperone: a new treatment approach for neuropsychiatric disorders. Drugs Today (barc). 2018;54(12):713-719.
  9. eHealth Medicare. Low-income subsidy––Medicare Extra Help Program. Accessed February 13, 2020. https://www.ehealthmedicare.com/medicare-part-d-articles/low-income-subsidy-medicare-extra-help-program.
  10. Centers for Medicare and Medicaid Services. Medicare Prescription Drug Benefit Manual: Chapter 13-Premium and cost-sharing subsidies for low-income individuals. Updated July 29, 2011. Accessed February 13, 2020. http://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/Chapter13.pdf.
  11. Medicare & Medicaid Services. Announcement of Calendar Year (CY) 2020 Medicare Advantage capitation rates and Medicare Advantage and Part D payment policies and final call letter. Published April 1, 2019. Accessed February 13, 2020. https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Announcement2020.pdf.